Changes in Cancer Incidence, Deaths Expected by 2040
Most common cancers will be breast, melanoma, and lung, while most common cause of cancer-related death will remain lung
Melanoma And Other Skin Cancers
Cavrotolimod Designated Orphan Drug for Merkel Cell Carcinoma
Cavrotolimod is a toll-like receptor 9 agonist that is designed to induce anticancer immune responses through proprietary spherical nucleic acid (SNA™) technology.
Fecal Transplant May Counter Anti-PD-1 Resistance in Melanoma
FMT plus anti-PD-1 therapy may change gut microbiome and help overcome drug resistance in some patients with advanced melanoma
FDA Approves Libtayo for Locally Advanced and Metastatic Basal Cell Carcinoma
The FDA has approved Libtayo for the treatment of patients with locally advanced and metastatic basal cell carcinoma (laBCC) who have previously received a hedgehog pathway inhibitor (HHI) or for whom an HHI is not appropriate
FDA-Approved Melanoma Treatments
FDA-approved drug therapies for cutaneous melanoma.
MPR Weekly Dose Podcast Episode 49
The ACIP release guidelines for the 2020-2021 vaccination recommendations; In COVID, there’s developments in convalescent plasma authorization, a 15 minute test, and ethnobotanist’s give a stark warning concerning a plant that some are touting as a cure. In other news an intrauterine device gains expanded approval and there’s a label update for hydrochlorothiazide.
FDA: Small Risk of Skin Cancer With Hydrochlorothiazide Use
Hydrochlorothiazide is indicated for the management of hypertension either as the sole therapeutic agent, or in combination with other antihypertensives.
Tecentriq Plus Cotellic and Zelboraf Approved for Advanced Melanoma
The approval was based on data from the multicenter, double-blind, placebo-controlled phase 3 IMspire150 study.
Pembrolizumab Use Supported in Advanced Melanoma
Use supported regardless of BRAF V600E/K mutation status, receipt of prior BRAFi with/without MEKi
Keytruda Approved for Cutaneous Squamous Cell Carcinoma
The FDA has approved Keytruda (pembrolizumab; Merck) for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.
